Literature DB >> 10197454

Density predicts the activity-dependent failure load of proximal femora with defects.

D A Michaeli1, K Inoue, W C Hayes, J A Hipp.   

Abstract

OBJECTIVE: To determine whether the load-bearing capacity of human proximal femora with metastatic defects can be predicted from the bone mineral content.
DESIGN: The bone mineral content (BMC) of the total proximal femur was measured by dual-energy X-ray absorptiometry (DXA). The femurs were loaded so as to simulate stair ascent or external rotation. PATIENTS: Simulated lytic defects were created using specialized cutting tools in the intertrochanteric region of 32 human cadaveric femora. Bone density measurements were made before and after creating defects.
RESULTS: A linear relation could be used to predict failure load from BMC or bone mineral density. The slope of the linear relation was greater for loads representing external rotation than for loads representing stair ascent. The linear relations suggest that the BMC measurements account for both the density of the host bone and the amount of bone removed by the defect.
CONCLUSIONS: The data suggest that between 70% and 80% of the variation in failure load of human femora with lytic metastatic defects can be predicted from the BMC and that relations between BMC and failure load are sensitive to the type of loading. Combined with information on the loads associated with the activities of daily living, these data may be used to help identify patients in whom prophylactic stabilization might prevent a pathologic fracture.

Entities:  

Mesh:

Year:  1999        PMID: 10197454     DOI: 10.1007/s002560050480

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN: 0364-2348            Impact factor:   2.199


  6 in total

1.  Treatment Planning and Fracture Prediction in Patients with Skeletal Metastasis with CT-Based Rigidity Analysis.

Authors:  Ara Nazarian; Vahid Entezari; David Zurakowski; Nathan Calderon; John A Hipp; Juan C Villa-Camacho; Patrick P Lin; Felix H Cheung; Albert J Aboulafia; Robert Turcotte; Megan E Anderson; Mark C Gebhardt; Edward Y Cheng; Richard M Terek; Michael Yaszemski; Timothy A Damron; Brian D Snyder
Journal:  Clin Cancer Res       Date:  2015-02-27       Impact factor: 12.531

2.  Does CT-based Rigidity Analysis Influence Clinical Decision-making in Simulations of Metastatic Bone Disease?

Authors:  Ara Nazarian; Vahid Entezari; Juan C Villa-Camacho; David Zurakowski; Jeffrey N Katz; Mary Hochman; Elizabeth H Baldini; Vartan Vartanians; Max P Rosen; Mark C Gebhardt; Richard M Terek; Timothy A Damron; Michael J Yaszemski; Brian D Snyder
Journal:  Clin Orthop Relat Res       Date:  2016-03       Impact factor: 4.176

3.  The insufficiencies of risk analysis of impending pathological fractures in patients with femoral metastases: A literature review.

Authors:  Emir Benca; Janina M Patsch; Winfried Mayr; Dieter H Pahr; Reinhard Windhager
Journal:  Bone Rep       Date:  2016-03-02

4.  Curved Beam Computed Tomography based Structural Rigidity Analysis of Bones with Simulated Lytic Defect: A Comparative Study with Finite Element Analysis.

Authors:  R Oftadeh; Z Karimi; J Villa-Camacho; E Tanck; N Verdonschot; R Goebel; B D Snyder; H N Hashemi; A Vaziri; A Nazarian
Journal:  Sci Rep       Date:  2016-09-02       Impact factor: 4.379

5.  QCT-based finite element prediction of pathologic fractures in proximal femora with metastatic lesions.

Authors:  Emir Benca; Alexander Synek; Morteza Amini; Franz Kainberger; Lena Hirtler; Reinhard Windhager; Winfried Mayr; Dieter H Pahr
Journal:  Sci Rep       Date:  2019-07-16       Impact factor: 4.379

6.  Bone management in Japanese patients with prostate cancer: hormonal therapy leads to an increase in the FRAX score.

Authors:  Takashi Kawahara; Shusei Fusayasu; Koji Izumi; Yumiko Yokomizo; Hiroki Ito; Yusuke Ito; Kayo Kurita; Kazuhiro Furuya; Hisashi Hasumi; Narihiko Hayashi; Yasuhide Myoshi; Hiroshi Miyamoto; Masahiro Yao; Hiroji Uemura
Journal:  BMC Urol       Date:  2016-06-17       Impact factor: 2.264

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.